Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis?
Authors:
- 8 May 2006
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 155 (1) , 213-214
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced MalignanciesJournal of Clinical Oncology, 2005
- Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth FactorActa Dermato-Venereologica, 2003
- Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumourBritish Journal of Dermatology, 2002
- A Central Role of Bcl-XL in the Regulation of Keratinocyte Survival by Autocrine EGFR LigandsJournal of Investigative Dermatology, 1999
- Detection of transforming growth factor alpha in normal, malignant, and hyperproliferative human keratinocytes.Journal of Experimental Medicine, 1988